Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. (300759)

Market Open
9 Dec, 06:57
XSHE XSHE
¥
29. 65
+0.52
+1.79%
¥
51.78B Market Cap
- P/E Ratio
0.8% Div Yield
9,668,800 Volume
- Eps
¥ 29.13
Previous Close
Day Range
28.94 29.9
Year Range
20.47 37.63
Want to track 300759 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

300759 trading today higher at ¥29.65, an increase of 1.79% from yesterday's close, completing a monthly increase of 2.45% or ¥0.71. Over the past 12 months, 300759 stock gained 14.79%.
300759 pays dividends to its shareholders, with the most recent payment made on Jul 04, 2025. The next estimated payment will be in In 6 months on Jul 04, 2026 for a total of ¥0.2.
The last earnings report, released on Oct 29, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.09%, based on the last three reports.
Pharmaron Beijing Co., Ltd. has completed 2 stock splits, with the recent split occurring on Jul 27, 2023.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSHE (CNY).

300759 Chart

Similar

Aier Eye Hospital Group Co. Ltd.
¥ 11.36
-0.35%
Haisco Pharmaceutical Group Co., Ltd.
¥ 61.07
-0.65%
Shannon Semiconductor Tech Inc.
¥ 146.76
+2.37%
Sichuan Kelun Pharmaceutical Co., Ltd.
¥ 32.68
-0.97%
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
¥ 65.11
+0.02%

Pharmaron Beijing Co., Ltd. (300759) FAQ

What is the stock price today?

The current price is ¥29.65.

On which exchange is it traded?

Pharmaron Beijing Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 300759.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.8%.

What is its market cap?

As of today, the market cap is 51.78B.

Has Pharmaron Beijing Co., Ltd. ever had a stock split?

Pharmaron Beijing Co., Ltd. had 2 splits and the recent split was on Jul 27, 2023.

Pharmaron Beijing Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Boliang Lou Ph.D. CEO
XSHE Exchange
CNE100003JW4 ISIN
CN Country
21,370 Employees
- Last Dividend
27 Jul 2023 Last Split
- IPO Date

Overview

Pharmaron Beijing Co., Ltd. is a prominent entity in the life sciences industry, offering comprehensive drug research, development, and production services across the globe, including North America, Europe, Japan, Mainland China, and other international markets. Since its incorporation in 2004, the company has been headquartered in Beijing, the People's Republic of China. With a broad network of subsidiaries, Pharmaron Beijing Co., Ltd. is dedicated to supporting the life sciences sector through its extensive range of services tailored to meet the complex demands of drug research and development.

Products and Services

Pharmaron Beijing Co., Ltd. specializes in a wide array of services within the drug research and development spectrum, categorized into laboratory chemistry services, bioscience services, clinical development services, and more. Each category encompasses specific services designed to cater to various aspects of drug development processes.

  • Laboratory Chemistry Services - These services cover a wide range of chemical analysis and synthesis needs, including:
    • Medicinal and Synthetic Chemistry - Focused on designing and synthesizing pharmacologically active molecules.
    • Chemistry for New Modalities - Tailoring chemical synthesis processes for innovative therapeutic modalities.
    • Radiolabelling and Radiosynthesis - Specializing in the incorporation of radioactive isotopes for tracing and study purposes.
    • Analytical and Purification Chemistry - Ensuring the purity and proper characterization of chemical substances.
    • DNA-Encoded Libraries - Utilizing DNA-encoded chemical libraries for rapid drug discovery.
    • Cheminformatics and Computer-Aided Drug Design - Employing computational tools to facilitate the drug design process.
  • Bioscience Services - Offering a comprehensive suite of bioscience research services, including:
    • Structural Biology - Determining the structure of biological molecules to guide drug design.
    • In Vitro Biology - Conducting experiments in a controlled environment outside of a living organism.
    • DMPK (Drug Metabolism and Pharmacokinetics) - Assessing the metabolic profile and distribution of drugs.
    • In Vivo Pharmacology - Evaluating the effects of substances in living organisms.
    • Compound Management Services - Providing comprehensive management solutions for chemical compounds.
  • Chemistry, Manufacturing, and Controls (CMC) Services - Ensuring the quality and regulatory compliance of drug manufacture and control procedures.
  • Clinical Development Services - Facilitating the clinical trial process through:
    • Integrated Radio Labelled Science - Combining radiolabelling with clinical research for detailed study analyses.
    • Clinical Development - Managing all phases of clinical trials from protocol design to regulatory submission.
    • Clinical Trial Recruitment Services - Specializing in the recruitment of suitable candidates for clinical trials.
  • Safety Assessment, Integrated Drug Discovery, and Bioanalysis Services - Offering a holistic approach to drug safety and efficacy analysis through comprehensive bioanalytical techniques.
  • Biologics and Cell and Gene Therapy Services - Providing specialized services for the development of biologics, and cell and gene therapies, including:
    • Biologics Laboratory - Focusing on the research and development of biological drugs.
    • Biologics CDMO - Offering Contract Development and Manufacturing Organization services for biologics.
    • Cell and Gene Therapy Laboratory - Dedicated to the research and development of cell and gene therapy products.
    • Gene Therapy CDMO - Providing specialized CDMO services for gene therapy products.

Contact Information

Address: Building 1, Beijing, China, 100176
Phone: 86 10 5733 0087